Hess Corporation Statistics
Total Valuation
DexCom has a market cap or net worth of $31.68 billion. The enterprise value is $32.39 billion.
Important Dates
The last earnings date was Wednesday, July 30, 2025, after market close.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 392.16 million shares outstanding. The number of shares has decreased by -2.97% in one year.
| Current Share Class | 392.20M |
| Shares Outstanding | 392.16M |
| Shares Change (YoY) | -2.97% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 94.76% |
| Float | 389.38M |
Valuation Ratios
The trailing PE ratio is 56.67 and the forward PE ratio is 34.32. DexCom's PEG ratio is 1.61.
| PE Ratio | 56.67 |
| Forward PE | 34.32 |
| PS Ratio | 8.12 |
| Forward PS | 6.49 |
| PB Ratio | 13.57 |
| P/TBV Ratio | 13.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.61 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 56.67 |
| EV / Sales | 7.53 |
| EV / EBITDA | 35.19 |
| EV / EBIT | 47.13 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.98.
| Current Ratio | 1.52 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.98 |
| Debt / EBITDA | 2.64 |
| Debt / FCF | n/a |
| Interest Coverage | 36.17 |
Financial Efficiency
Return on equity (ROE) is 22.83% and return on invested capital (ROIC) is 8.48%.
| Return on Equity (ROE) | 22.83% |
| Return on Assets (ROA) | 6.08% |
| Return on Invested Capital (ROIC) | 8.48% |
| Return on Capital Employed (ROCE) | 17.10% |
| Revenue Per Employee | $417,553 |
| Profits Per Employee | $55,485 |
| Employee Count | 10,300 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 3.05 |
Taxes
In the past 12 months, DexCom has paid $212.60 million in taxes.
| Income Tax | 212.60M |
| Effective Tax Rate | 27.11% |
Stock Price Statistics
The stock price has increased by +16.20% in the last 52 weeks. The beta is 1.45, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | +16.20% |
| 50-Day Moving Average | 84.86 |
| 200-Day Moving Average | 79.12 |
| Relative Strength Index (RSI) | 38.50 |
| Average Volume (20 Days) | 2,836,185 |
Short Selling Information
The latest short interest is 8.89 million, so 2.27% of the outstanding shares have been sold short.
| Short Interest | 8.89M |
| Short Previous Month | 10.51M |
| Short % of Shares Out | 2.27% |
| Short % of Float | 2.28% |
| Short Ratio (days to cover) | 2.35 |
Income Statement
In the last 12 months, DexCom had revenue of $4.30 billion and earned $571.50 million in profits. Earnings per share was $1.42.
| Revenue | 4.30B |
| Gross Profit | 2.53B |
| Operating Income | 687.20M |
| Pretax Income | 806.90M |
| Net Income | 571.50M |
| EBITDA | 920.30M |
| EBIT | 687.20M |
| Earnings Per Share (EPS) | $1.42 |
Full Income StatementBalance Sheet
The company has $2.93 billion in cash and $2.52 billion in debt, giving a net cash position of $406.20 million or $1.04 per share.
| Cash & Cash Equivalents | 2.93B |
| Total Debt | 2.52B |
| Net Cash | 406.20M |
| Net Cash Per Share | $1.04 |
| Equity (Book Value) | 2.57B |
| Book Value Per Share | 6.56 |
| Working Capital | 1.72B |
Full Balance SheetMargins
Gross margin is 58.77%, with operating and profit margins of 15.98% and 13.29%.
| Gross Margin | 58.77% |
| Operating Margin | 15.98% |
| Pretax Margin | 18.23% |
| Profit Margin | 13.29% |
| EBITDA Margin | 21.40% |
| EBIT Margin | 15.98% |
| FCF Margin | n/a |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.97% |
| Shareholder Yield | 2.97% |
| Earnings Yield | 1.74% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for DexCom is $99.89, which is 23.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $99.89 |
| Price Target Difference | 23.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 14.41% |
| EPS Growth Forecast (5Y) | 26.22% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
